- Home
- WYHG vs CNTX Comparison
WYHG vs CNTX Comparison
Compare WYHG & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- CNTX
- Stock Information
- Founded
- WYHG 1915
- CNTX 2015
- Country
- WYHG China
- CNTX United States
- Employees
- WYHG N/A
- CNTX N/A
- Industry
- WYHG
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- CNTX Health Care
- Exchange
- WYHG NYSE
- CNTX Nasdaq
- Market Cap
- WYHG 77.0M
- CNTX 78.0M
- IPO Year
- WYHG 2024
- CNTX 2021
- Fundamental
- Price
- WYHG $1.39
- CNTX $0.63
- Analyst Decision
- WYHG
- CNTX Strong Buy
- Analyst Count
- WYHG 0
- CNTX 5
- Target Price
- WYHG N/A
- CNTX $5.50
- AVG Volume (30 Days)
- WYHG 205.3K
- CNTX 330.3K
- Earning Date
- WYHG 08-15-2025
- CNTX 08-06-2025
- Dividend Yield
- WYHG N/A
- CNTX N/A
- EPS Growth
- WYHG N/A
- CNTX N/A
- EPS
- WYHG 0.20
- CNTX N/A
- Revenue
- WYHG $147,996,867.00
- CNTX N/A
- Revenue This Year
- WYHG N/A
- CNTX N/A
- Revenue Next Year
- WYHG N/A
- CNTX N/A
- P/E Ratio
- WYHG $4.49
- CNTX N/A
- Revenue Growth
- WYHG 19.02
- CNTX N/A
- 52 Week Low
- WYHG $1.10
- CNTX $0.49
- 52 Week High
- WYHG $12.00
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- CNTX 50.76
- Support Level
- WYHG N/A
- CNTX $0.62
- Resistance Level
- WYHG N/A
- CNTX $0.70
- Average True Range (ATR)
- WYHG 0.00
- CNTX 0.05
- MACD
- WYHG 0.00
- CNTX 0.01
- Stochastic Oscillator
- WYHG 0.00
- CNTX 56.44
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The main categories of products are cured meat products, including cured pork sausages, cured pork meat and other cured meat products, such as cured chicken, cured duck and cured fish; snack products, including ready-to-eat sausages, jerky, duck necks, duck feet and claypot rice; and frozen meat products, including frozen sausages, frozen beef patties and frozen chicken breast fillets.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.